We are a Canadian-based biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. We are a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. Our core technology aims to repair neurological function lost due to diseases such as stroke, traumatic brain injury, multiple sclerosis and other neurodegenerative conditions.

We, at SCT, operate on the basis of four key principles:

1.  Develop cutting edge stem cell science;
2.  Design efficient drug development approachs;
3.  Target large unmet medical needs;
4.  Create a team with the right experience to achieve success.